E-ISSN: 1305-3612
MRI/US fusion-guided prostate biopsy allows for equivalent cancer detection with significantly fewer needle cores in biopsy-naive men
PDF
Cite
Share
Request
Abdominal Radiology - Original Article
VOLUME: 24 ISSUE: 3
P: 115-120
May 2018

MRI/US fusion-guided prostate biopsy allows for equivalent cancer detection with significantly fewer needle cores in biopsy-naive men

Diagn Interv Radiol 2018;24(3):115-120
DOI: 10.5152/dir.2018.17422
Vidhush K. Yarlagadda 1
Win Shun Lai 1
Jennifer B. Gordetsky 2
Kristin K. Porter 3
Jeffrey W. Nix 1
John V. Thomas 3
Soroush Rais-Bahrami 4
1. Department of Urology, University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA
2. Department of Urology, University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA; Department of Pathology, University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA
3. Department of Radiology, University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA
4. Department of Urology, University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA; Department of Radiology, University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA
No information available.
No information available
Received Date: 19.11.2017
Accepted Date: 13.02.2017
PDF
Cite
Share
Request

ABSTRACT

PURPOSE:

We aimed to investigate the efficiency and cancer detection of magnetic resonance imaging (MRI) / ultrasonography (US) fusion-guided prostate biopsy in a cohort of biopsy-naive men compared with standard-of-care systematic extended sextant transrectal ultrasonography (TRUS)-guided biopsy.

METHODS:

From 2014 to 2016, 72 biopsy-naive men referred for initial prostate cancer evaluation who underwent MRI of the prostate were prospectively evaluated. Retrospective review was performed on 69 patients with lesions suspicious for malignancy who underwent MRI/US fusion-guided biopsy in addition to systematic extended sextant biopsy. Biometric, imaging, and pathology data from both the MRI-targeted biopsies and systematic biopsies were analyzed and compared.

RESULTS:

There were no significant differences in overall prostate cancer detection when comparing MRI-targeted biopsies to standard systematic biopsies (P = 0.39). Furthermore, there were no significant differences in the distribution of severity of cancers based on grade groups in cases with cancer detection (P = 0.68). However, significantly fewer needle cores were taken during the MRI/US fusion-guided biopsy compared with systematic biopsy (63% less cores sampled, P < 0.001)

CONCLUSION:

In biopsy-naive men, MRI/US fusion-guided prostate biopsy offers equal prostate cancer detection compared with systematic TRUS-guided biopsy with significantly fewer tissue cores using the targeted technique. This approach can potentially reduce morbidity in the future if used instead of systematic biopsy without sacrificing the ability to detect prostate cancer, particularly in cases with higher grade disease.